Cyclin D1 is an important regulator of the transition from G1 into S phase of the cell cycle. The level to which cyclin D1 accumulates is tightly regulated. One mechanism contributing to the control of cyclin D1 levels is the regulation of its ubiquitination. SK-UT-1B cells are de®cient in the degradation of D-type cyclins. We show here that p27, a substrate of the SCF Skp2 ubiquitin ligase complex, is coordinately stabilized in SK-UT-1B cells. Further, we show that expression of Skp2 in SK-UT-1B cells rescues the cyclin D1 and p27 degradation defect observed in this cell line. These results therefore indicate that the SCF Skp2 ubiquitin ligase complex aects the ubiquitination of cyclin D1. In addition, we show that SK-UT-1B cells express a novel splice variant of Skp2 that localizes to the cytoplasm and that cyclin D1 ubiquitination takes place in the nucleus. We propose that the translocation of Skp2 into the nucleus is required for the ubiquitination of cyclin D1 and that the absence of the SCF Skp2 complex in the nucleus of SK-UT-1B cells is the mechanism underlying the ubiquitination defect observed in this cell line. Finally, our data indicates that dierential splicing of F-box proteins may represent an additional level of regulation of the F-box mediated ubiquitination pathway. Oncogene (2001) 20, 3641 ± 3650.
Introduction
Mammalian cells must integrate a plethora of signals generated by extracellular growth factors, mitogen antagonists and dierentiation inducers in order to decide whether or not to commit to S phase entry. Therefore, the mechanisms by which cells integrate mitogenic and antiproliferative signals are crucial to maintain cellular integrity. The importance of such mechanisms is best illustrated by the fact that alteration to the control of G1-S phase transition is the most frequent defect observed in human cancers. At the heart of this regulation is the pathway regulating the phosphorylation of the retinoblastoma protein (Rb) (for a review, Weinberg, 1995) . Rb phosphorylation, catalysed by a D-type cyclin and the cyclin dependent kinases (CDK 4, 6) , results in the release of the E2F family of transcription factors and activation of expression of genes required for entry into S phase (for a review, Helin, 1998) . Cyclin E-CDK2 complexes act downstream of cyclin D-CDK4 to maintain Rb phosphorylation (Lundberg and Weinberg, 1998) . Premature activation of cyclin E-CDK2 complex enables cells to bypass the restriction point. However, the activity of cyclin E-CDK2 complex can be restricted by binding to the CDK inhibitors (CKI) p27 and p21 (for a review, Sherr and Roberts, 1995) .
The importance of cyclin E and D-type cyclins in the regulation of the G1 into S phase transition suggests that their overexpression may contribute to cellular proliferation and oncogenesis. In agreement with this observation, overexpression of cyclin D1 or cyclin E in mouse mammary glands leads to carcinoma (Wang et al., 1994; Bortner and Rosenberg, 1997) . In human breast cancer, abnormal accumulation of cyclin D1 is observed in up to 35% of cases. Mechanisms by which cyclin D1 is overexpressed include ampli®cation and translocation of the cyclin D1 gene (Lammie et al., 1991; Motokura and Arnold, 1993; Motokura et al., 1991) and stabilization of cyclin D1 mRNA (Lebwohl et al., 1994) . We have shown that in addition to these mechanisms, defects in the degradation of cyclin D1 contribute to cyclin D1 overexpression in *15% of breast cancers (Russell et al., 1999) . These defects in proteolysis of cyclin D1 are seen in the uterine cell lines SK-UT1 and SK-UT-1B (Welcker et al., 1996) due the loss of cyclin D1 ubiquitination (Germain et al., 2000) .
D-type cyclins, cyclin E, E2F-1, p27 and p21 are all ubiquitinated and targeted for degradation by the 26S proteasome. Phosphorylation appears to be an important step in the regulation of ubiquitination. Cyclin D1 is phosphorylated on threonine 286 by the glycogen synthase kinase 3b (GSK-3b) and this phosphorylation event is required for its ubiquitination (Diehl et al., 1998) . In recent years, intense eorts have been made to elucidate the machinery responsible for the degradation of proteins involved in the control of the G1 phase. Studies in yeast have led to the identi®cation of complexes called SCFs, that are multiprotein ubiquitin ligases responsible for the ubiquitination and subsequent degradation of both G1 cyclins and the CDK inhibitor Sic1 (for a review; Krek, 1998) . SCF complexes are highly conserved in higher eukaryotes. Their cores consist of three proteins; a cullin, Skp1 and a ring ®nger protein, Rbx1 (Tyers and Willems, 1999) . Mammalian cells encode at least six cullins, several putative Skp1 homologues and a large number of ring ®nger proteins. Therefore, several potential SCF cores may be present in cells. Disruption of the cul-1 and cul-3 genes in mice results in embryonic lethality (Dealy et al., 1999; Wang et al., 1999) , suggesting that disruption of the SCF core aects a vast number of proteins. Speci®city of these ubiquitin ligases is conferred by substrate-speci®c adaptor subunits called F-box proteins. Mammalian cells express a large number of F-box proteins, that fall into three families. As this large number of F-box proteins holds the potential to bind to dierent SCF cores, the combinatorial assembly of SCF complexes represents a mechanism by which a speci®c group of proteins can be targeted for ubiquitination. Skp2 is an F-box protein that associates with a SCF complex designated as SCF SKP2 complex. The SCF core is localized to the cytoplasm until Skp2 is expressed in late G1 and localizes the SCF SKP2 complex into the nucleus, where it promotes the ubiquitination of selected proteins (Lisztwan et al., 1998) . The SCF SKP2 complex has been shown to be involved in the ubiquitination of the CDK inhibitor p27 (Carrano et al., 1999; Sutterluty et al., 1999) and to be overexpressed in transformed but not in non-transformed cell lines (Zhang et al., 1995) . These ®ndings led to the hypothesis that the overexpression of Skp2 promotes the degradation of p27 and therefore results in S phase entry by promoting activation of cyclin E-CDK2 (Amati and Vlach, 1999) .
However, more recently the analysis of Skp2 knockout mice has revealed that the loss rather than the overexpression of Skp2 may contribute to tumorigenesis (Nakayama et al., 2000) . Further, cyclin E and to a lesser extent cyclin D1 are also elevated in Skp27/7 cells (Nakayama et al., 2000) in addition to p27. However, the involvement of Skp2 in the ubiquitination of cyclin D1 remains controversial since despite the elevation of cyclin D1 in Skp27/7 MEFs and the observation that expression of Skp2 anti-sense results in elevated levels of cyclin D1 (Yu et al., 1998) , no direct association between Skp2 and cyclin D1 has been observed (Carrano et al., 1999; Nakayama et al., 2000) .
We describe here that expression of Skp2 in SK-UT-1B cells rescues the ubiquitination of cyclin D1. This result supports the involvement of Skp2 in the ubiquitination of cyclin D1 and in agreement with this hypothesis, we ®nd that p27 is also stabilized in SK-UT-1B cells. Further, analysis of endogenous Skp2 in this cell line has lead to the isolation of a new splice variant of Skp2 with an alternative C-terminus, we named Skp2-CTV (C-terminal variant). In contrast to Skp2, Skp2-CTV is unable to localize the SCF to the nucleus, remains in the cytoplasm and fails to bind to Skp1. As the expression of Skp2 is lost in SK-UT-1B cells our data strongly suggests that inactivation of Skp2 results in a defect in the ubiquitination of both D-type cyclins and p27, raising the possibility that their degradation is coordinated.
Results

p27 degradation is reduced in the uterine cell line SK-UT-1B
The uterine cell line SK-UT-1 (pRb de®cient) and SK-UT-1B (pRb-positive) are defective in the degradation of cyclin D1 (Welcker et al., 1996) and we previously showed that this is due to a defect in cyclin D1 ubiquitination (Germain et al., 2000) . We reasoned that if cyclin D1 is ubiquitinated by the SCF Skp2 ubiquitin ligase complex, then the ubiquitination of other known substrates of Skp2 may also be defective in these cell lines. Proposed substrates of the SCF Skp2 ubiquitin ligase include the CDK inhibitor p27 (Carrano et al., 1999; Sutterluty et al., 1999; Tsvetkov et al., 1999) , cyclin E (Nakayama et al., 2000) , the transcription factor E2F-1 and Cyclin D1 (Yu et al., 1998) . To address this question, protein from U2OS and SK-UT-1B cells were extracted and analysed by Western blotting. As was observed for cyclin D1, the protein levels of p27 were elevated in SK-UT-1B cells compared to U2OS cells (Figure 1a ) however, no signi®cant dierence in cyclin E and E2F-1 were seen (Figure 1a ). To investigate whether the increased levels of p27 observed in SK-UT-1B cells correlated with the ubiquitination activity present in these cells, we performed an in vitro ubiquitination assay as described previously (13) S-p27 with SK-UT-1B extracts failed to promote the formation of high molecular forms of p27. We found that both U2OS and SK-UT-1B extracts were able to promote the formation of high molecular weight forms of 35 S-E2F-1 (Figure 1b) . These results indicate that SK-UT-1B extracts failed to promote the ubiquitination of p27 and does not represent a general loss of activity in these extracts. The result obtained using the in vitro ubiquitination assay is consistent with the endogenous levels of p27 and E2F-1 observed in U2OS and SK-UT-1B and suggests that the turnover of p27 may be defective in SK-UT-1B. To further address this question, the halflife of p27 was determined in SK-UT-1B and in MDA-MB 231 cells, a cell line expressing similar levels of p27 compared to SK-UT-1B cells. The half-life of p27 was less than 2 h in MDA-MB 231 cells, while it was still present up to 6 h in SK-UT-1B cells (Figure 1c ). These results indicated that SK-UT-1B cells have a defect in both the degradation of D-type cyclins (Welcker et al., 1996) and p27, raising the possibility that their degradation is coordinated.
Expression of Skp2 in SK-UT-1B cells rescues cyclin D1 ubiquitination
The involvement of an SCF ubiquitin ligase complex in the ubiquitination of G1 cyclins has been well documented in yeast (Bai et al., 1996; Deshaies et al., 1995; Skowyra et al., 1997 Skowyra et al., , 1999 . In mammalian cells, two observations suggest that this process is conserved; ®rst, the expression of anti-sense Skp2 results in the accumulation of cyclin D1 (Yu et al., 1998) . Second, analysis of Skp2 de®cient cells also shows a modest elevation in the levels of cyclin D1 (Nakayama et al., 2000) . To further address the eect of Skp2 in the degradation of cyclin D1, we established stable SK-UT-1B cell lines expressing Skp2 and analysed the eect of Skp2 on cyclin D1 level. The level of cyclin D1 was lower in the Skp2 expressing cell line ( Figure 2a , lane 2) compared to the parental cell line (Figure 2a , lane 1). This result was obtained in two independent clones indicating that the expression of Skp2 rescued the defect in cyclin D1 turnover. To further test this possibility, we tested the ubiquitination of cyclin D1 in SK-UT-1B cell line expressing Skp2. Upon transfection of Myc-Ubiquitin ubiquitinated cyclin D1 was detected ( Figure 2b ). We then determined the half-life of cyclin D1 in the Skp2 stable cell line and found that cyclin D1 protein was degraded by 1 h where as in the parental cell line cyclin D1 protein was still stabilized at 3 h ( Figure 2c ). These results indicate that expression of Skp2 in SK-UT-1B cells rescues the cyclin D1 proteolysis defect and are consistent with a defect in Skp2 in this cell line.
The eect of Skp2 expression on p27, E2F-1 and cyclin E levels was also determined in the stable cell line. As expected, the levels of p27 was decreased in this cell line ( Figure 2a , lane 2) compared to the (Figure 2d ). However, in agreement with our previous observation, no dierence in the level of cyclin E or E2F-1 was observed. We concluded that stable expression of Skp2 in SK-UT-1B cells rescues the degradation of both cyclin D1 and p27, suggesting that their ubiquitination are directly or indirectly coordinated.
Identification of a splicing variant of Skp2 in SK-UT-1B cells
We then cloned the Skp2 cDNA from SK-UT-1B cells using RT ± PCR. Although we could amplify Skp2 cDNA using a primer 5' to the ATG with multiple 3' primers, we failed to amplify the full length Skp2 cDNA in this cell line. Control PCRs successfully ampli®ed the full length cDNA in other cell lines (data not show). This observation indicated that the Cterminal end of the Skp2 cDNA may be dierent in SK-UT-1B cells. We utilized 3' RACE to identify the C-terminal portion of Skp2. As predicted from our inability to amplify full length Skp2 clone, 3' RACE analysis revealed the presence of a novel sequence. This sequence diers from the Skp2 sequence at amino acid 365 and interrupts the sixth and seventh leucine rich regions (LRR) and the remaining C-terminal domain of Skp2. As Skp2 maps to chromosome 5 (Demetrick et al., 1996) , we then analysed the karyotype of SK-UT-1B cells for potential rearrangement on chromosome 5. However, no major changes were observed (data not shown). Further, Southern analysis of the Skp2 locus also failed to reveal genomic rearrangements suggesting that the new sequence may have arisen by dierential splicing. In agreement with this hypothesis, analysis of the complete human Skp2 genomic clone (Figure 3a,b) indicated that the sequence diverges at an intron ± exon boundary (nucleotide 1241 of Skp2 cDNA) and that the new sequence is encoded by an exon situated approximately 1.6 kb downstream of the exon encoding the previously reported C-terminal domain of Skp2 (Figure 3a,b) . This result indicates that Skp2 has two dierent Cterminal domains that are encoded by two distinct exons and so to avoid confusion we refer to these exons as C-terminal 1 and 2 (CT1 and CT2) ( Figure  4c ). We named the Skp2 protein that results from splicing to exon CT2 as Skp2-CTV (C-terminal variant). The Skp2-CTV created an in frame fusion protein of 422 amino acids (Figure 3d ), that is undistinguishable by size under the conditions used here to the previously described Skp2 protein using and antibody directed toward the N-terminal domain of Skp2 (Figure 3e ). However, in agreement with our hypothesis that Skp2-CTV is the predominant form of Skp2 in SK-UT-1B cells, Skp2 was not recognized by an antibody directed towards the C-terminal part of Skp2 in these cells (Figure 3e ). The divergent sequence (Figure 3f ) shows no homology to any known proteins, or motifs in the database, although it corresponds to several EST's from dierent sources, indicating that it is expressed in several tissues. Further, ®ve EST's (accession numbers; BE671874, BE207770, AW237034, AI673076, BE253981) corresponded to the fusion between Skp2 and the new sequence, suggesting that this variant represents a frequent splice form of Skp2. In agreement with this hypothesis, Skp2-CTV was expressed in various cell lines we examined (data not show) including U2OS cells. Therefore as U2OS also express the previous describe form of Skp2 (Figure 3e ), this result indicates that the expression of Skp2 and Skp2-CTV is not mutually exclusive. As Skp2-CTV appears to be the predominant form of Skp2 present in SK-UT-1B cells, this result suggests that splicing at the CT1 exon may be de®cient in SK-UT-1B cells. To test this possibility we screened the sequence spanning the intron-CT1 exon boundary of SK-UT-1B cells for a mutation. This analysis revealed no dierence between the SK-UT-1B and U2OS genomic sequence (data not shown), suggesting that a more general gene splicing problem may exist in this cell line.
Skp2-CTV fails to localize Cul-1 to the nucleus
Recently, the ubiquitination of p27 has been found to be take place in the nucleus (Swanson et al., 2000) . To examine the cellular compartment in which cyclin D1 becomes ubiquitinated. U2OS cells were transfected with a plasmid expressing cyclin D1
HA with or without a plasmid expressing Myc-ubiquitin and the presence of ubiquitinated cyclin D1 HA was determined in cytosolic or nuclear fractions. The majority of the ubiquitinated cyclin D1
HA was found in the nuclear fractions (Figure 4 , right panel), although some ubiquitinated cyclin D1
HA was found in the cytoplasmic fraction ( Figure 5 , right panel), Considering that Skp2 localizes to the nucleus (Lisztwan et al., 1998) and that the ubiquitination of cyclin D1 occurs in the nucleus, this result is consistent with the involvement of Skp2 in this process.
Further, these results raise the possibility that the defect in cyclin D1 ubiquitination observed in SK-UT-1B cells is due to the mislocalization of Skp2-CTV. As reported previously (Lisztwan et al., 1998) , Skp2 localized to the nucleus (Figure 5c ). In contrast, we found that Skp2-CTV remained in the cytoplasm (Figure 5e ). Further, as described in a previous study, expression of Skp2 leads to the translocation of Cul-1 into the nucleus (Lisztwan et al., 1998) . Data shown in Figure 5 con®rms this observation. Cul-1 HA localizes to the cytoplasm when expressed alone in U2OS cells (Figure 5b) . However, upon expression of Skp2, both Skp2 and Cul-1 localize to the nucleus (Figure 5c, d) . In contrast, Cul-1 HA remained in the cytoplasm when cotransfected with Skp2-CTV (Figure 5f ). This result indicates that nuclear localization of Skp2 is required for Cul1 to localize to the nucleus. Analysis of the Cterminal domain of Skp2 revealed a potential nuclear localization signal that is absent in Skp2-CTV. However, we found that a mutant form of Skp2 (Skp2 DC), where a stop codon introduced at the point of divergence between Skp2 and Skp2-CTV, still localizes to the nucleus (Figure 5g) , indicating that the sequence required for the nuclear localization of Skp2 is not part of the C-terminal domain. Therefore, this raises the possibility that the C-terminal domain of Skp2-CTV contains a cytoplasmic retention domain that is dominant over the nuclear localization signal of Skp2.
Skp2-CTV fails to bind to Skp1
Recently, the structure of the Skp1-Skp2 complex has been determined and indicated a role for the Cterminal domain of Skp2 for the association with Skp1 (Schulman et al., 2000) . For the wild-type protein, there is a bipartite interface between Skp1 and Skp2. In the ®rst part of the interface, the F-box binds to conserved residues among Skp1 family members. In the second part of the interface, the Fbox, leucine-rich repeats and extreme C-terminus of Skp2 form a groove which binds to the extreme Cterminus of Skp1. This second part of the interface dramatically stabilized the interaction between Skp2 and Skp1, and it is important for SCF function in vivo in yeast (Schulman et al., 2000) . As Skp2-CTV lacks the wild-type extreme C-terminus, this second part of the interface, if formed at all, would not be the same as for the wild-type proteins. Therefore, it is likely that the ability of Skp2-CTV to bind Skp1 would be reduced. To directly assess whether the association with Skp1 is disrupted by the presence of the alternative C-terminal domain of Skp2-CTV, the binding of Skp2 and Skp2-CTV to Skp1 was measured by a GST binding assay. In agreement with the predicted structure of Skp2-CTV, we found that the binding between GST-Skp1 and Skp2-CTV was drastically lower (Figure 6b , lane 4) compared to the binding between GST-Skp1 and Skp2 (Figure 6b , lane 2). To con®rm this result, Skp2 was immunoprecipitated from U2OS and SK-UT-1B cells using an antibody directed toward the N-terminal of Skp2 and the co-immunoprecipitation of Skp1 tested by Western analysis. In U2OS cells, Skp1 was detected following Skp2 immunoprecipitation (Figure 6c, lane 1) . However, only very low level of Skp1 was detected when Skp2 was immunoprecipitated from SK-UT-1B cells (Figure 6c , lane 2) despite the fact that both cell lines express similar level of Skp1 protein (Figure 6d ). These results indicate that in addition to the inability of Skp2-CTV to localize to the nucleus, this alternative form of Skp2 is also unable to bind to Skp1 eciently despite the presence of an intact F-box motif. 
Discussion
Our results suggest that Skp2 aects the ubiquitination of cyclin D1. Evidence supporting this conclusion are that: (i), p27, a known substrate of SCF Skp2 is stabilized in SK-UT-1B cell line; (ii), expression of Skp2 in SK-UT-1B cells rescues the cyclin D1 and p27 degradation defect of this cell line; (iii), cyclin D1 ubiquitination takes place in the nucleus where Skp2 is localized; (iv), SK-UT-1B cells express a splicing variant of Skp2 that localizes to the cytoplasm and fails to bind Skp1 eciently.
Previous studies have shown that cyclin D1 is nuclear during the G1 phase of the cell cycle and is translocated to and degraded in the cytoplasm upon entry into S phase (Diehl et al., 1998) . Ubiquitination of cyclin D1 requires phosphorylation by glycogen synthase kinase 3b (GSK-3b) on threonine 286. While GSK-3b is localized in the cytoplasm during G1 upon entry into S phase GSK-3b translocates into the nucleus leading to the degradation of cyclin D1 by the 26S proteasome (Diehl et al., 1998) . Figure 7 proposes a model for the regulation of cyclin D1 phosphorylation by GSK-3b and Skp2 mediated ubiquitination. Our data shows that in addition to the translocation of GSK-3b into the nucleus, when Skp2 is stabilized at the G1-S transition (Lisztwan et al., 1998) (Wirbelauer et al., 2000) , it binds to the core of the SCF ubiquitin ligase and relocalizes this complex into the nucleus (Lisztwan et al., 1998) and Figure 7 . As Skp2-CTV localized to the cytoplasm, fails to bind Skp1 and does not promote nuclear localization of Cul-1, our data suggests that the presence of the nuclear form of Skp2 is required for the ubiquitination of cyclin D1. How Skp2 aects cul-1 localization remains to be determined. Although our data indicates a role for Skp2 in the ubiquitination of cyclin D1, we do not demonstrate the direct involvement of the SCF Skp2 complex in the ubiquitination of cyclin D1. The possibility exists that a defect in Skp2 aects cyclin D1 ubiquitination indirectly by leading to the stabilization of an inhibitor of cyclin D1 ubiquitination. Our data cannot distinguish between these two possibilities. Further experiments using puri®ed components would be required to test this point. Nevertheless, in terms of tumour biology our data demonstrates that when Skp2 is absent, D-type cyclins and p27 are coordinately elevated. This has important biological implications as D-type cyclins titrate p27 away from cyclin E-cdk2 complexes, contributing to the activation of this complex (Bouchard et al., 1999; Perez-Roger et al., 1999) . In addition, as p27 serves as an assembly factor for the D-type cyclin-cdk4, 6 complexes (Cheng et al., 1999; LaBaer et al., 1997) , their coordinated elevation may also promote cellular proliferation. Further, our results are consistent with p27 and cyclin D1 elevation in Skp27/7 cells (Nakayama et al., 2000) . However, in contrast to what was observed in Skp27/7 cells, SK-UT-1B does not show elevation in cyclin E level. Further, while E2F-1 has been suggested to be a substrate of Skp2, elevation in E2F-1 levels was not observed in either Skp27/7 cells or SK-UT-1B cells. The reason for these discrepancies is unclear but considering the very large number of existing F box proteins, it may simply re¯ect the dierential expression of F box proteins other than Skp2 with overlapping speci®city for cyclin E in uterine tissue.
Skp2-CTV unlike Skp2 localizes to the cytoplasm. Further, as Skp2-CTV is expressed in a variety of cell types and represents a frequent splicing variant it is tempting to speculate that it may have a distinct function in the cytoplasm. Considering that the Cterminal portion of Skp2 was recently shown to be important for binding to the core of the SCF by interacting with Skp1 (Schulman et al., 2000) and that we found that Skp2-CTV does not bind Skp1 eciently, the presence of an alternative C-termini in Skp2-CTV may allow binding to proteins other than Skp1. In agreement with this hypothesis, extracts from SK-UT-1B cells are unable to ubiquitinate cyclin D1 in an in vitro assay (Germain et al., 2000) , indicating that Skp-2-CTV alters Skp2 function in addition to its localization. If so, the discovery of Skp2-CTV raises the possibility that in addition to the large diversity that the combinatorial assembly of SCF complexes oer, dierential splicing of F-box proteins may add another level of complexity to the regulation of Finally, although previous studies have led to the hypothesis that Skp2 overexpression is oncogenic, our results and analysis of Skp27/7 cells indicate that loss of Skp2 may also contribute to tumorigenesis. Determining the complete subset of proteins aected by Skp2 mediated ubiquitination and de®ning the expression pattern of potentially overlapping F-box proteins in various tissues will be important to clarify the role of Skp2 in cancer progression.
Material and methods
Cell culture, plasmids and transfections U2OS and SK-UT-1B cells were grown in Dulbecco's modi®ed Eagle medium supplemented with 10% foetal calf serum, glutamine and antibiotics (Life Technologies, Inc.). cDNA fragments encoding the coding sequence of cyclin D1 HA , Cul-1 HA , Skp2, Skp2-CTV and ubiquitin MYC were cloned in the pCDNA3 expression vector (Invitrogen).
Transfection of plasmids into U2OS and SK-UT-1B cells was performed by lipofection using the FuGENE TM 6 system, as described by the manufacturer (Boehringer ± Mannheim).
3'RACE and RT ± PCR
For cloning of the Skp2-CTV, RNA was extracted from SK-UT-1B cells using Trizol reagent (Gibco ± BRL) and used in the 3'RACE system (Gibco BRL cat no. 18373-027) for ®rst-strand cDNA synthesis according to the manufacturer's instructions (Gibco ± BRL). For ampli®cation of the Skp2-CTV cDNA, a ®rst round of PCR was performed using Skp2 sense primer P9:5'-GCTGTCCCAGACTGGATGAGCT-GAACCTCTCCTGG-3' corresponding to nucleotides 794 ± 828 of SKP2 sequence and the reverse primer UAP (3'RACE system). The resulting 500 base pair fragment was puri®ed and in a second round of PCR was performed using Skp2 sense primer P10 : 5'-GGTGGCTGTTGCGCATGTCTCA-GAGACCATGACCCAGO-3' corresponding to nucleotides 858 ± 894 of the Skp2 sequence (no. HSU33761). For both PCR, 35 cycles of 1 min 958C, 1 min 658C, 1 min 728C, were preceded by a step of 3 min at 958C and followed by a 3 min at 728C incubation. The 500 base pair fragment was puri®ed and used for sequencing with the P10 primer. Once the Skp2-CTV sequence determined, the full-length cDNA encoding the Skp2-CTV was obtained by RT ± PCR reaction using the Titan one tube RT-PCR system (Boehringer ± Mannheim). For the PCR, 35 cycles of 1 min 958C, 1 min 608C, 1 min 728C, were preceded by a step of 3 min at 958C and followed by a 3 min at 728C incubation.
Immunoprecipitations and Western blotting
Protein extracts from cell lines, were prepared by washing the cells from a 10 cm dish three times in ice cold phosphatebuered saline (PBS), followed by lysis in 300 ml of NP-40 lysis buer (50 mM Tris pH 7.5, 250 mM NaCl, 5 mM EDTA 0.5% NP40, 0.1 mM sodium¯uoride, 0.2 mM sodium orthovanadate, 1 mM dithiothreitol) containing the protease inhibitors (1 mg/ml Aprotinin, 1 mg/ml Leupeptin, 1 mg/ml Pepstatin, 100 mg/ml PMSF, 100 m/ml TPCK). The lysates were clari®ed by centrifugation at 13 000 g for 20 min at 48C. The protein concentration of the supernatant was assayed using a BCA Kit (Pierce).
A 30 mg aliquot of each lysate was diluted in SDS ± PAGE sample buer, the proteins denatured for 5 min at 958C, then fractionated on a 12% polyacrylamide gel, transferred onto a nitrocellulose membrane and subjected to standard Western blotting analysis using the primary antibodies. For detection of cyclin D1 by immunoblotting, the rabbit polyclonal antibody M-20 (Santa Cruz) was used at a dilution of 1 : 100. Myc tagged ubiquitin, was detected using the mouse monoclonal antibody, 9E10. The haemaglutinin (HA) epitope was detected using the rat monoclonal antibody 3F10 (Boehringer ± Mannheim) at a dilution of 1 : 250. Skp2 protein was detected using either the goat polyclonal amino (N-19) antibody or C-terminal antibody (C20) (Santa Cruz) at 1 : 100. p27 protein was detected using the anti-rabbit polyclonal antibody C-19 (Santa Cruz) at a dilution of 1 : 100. The bound primary antibodies were visualized using anti-rat, anti-mouse or anti-rabbit-conjugated horseradish peroxidase secondary antibodies (Amersham) at a dilution of 1 : 3000 and chemiluminescence (ECL Kit, Amersham).
For immunoprecipitation, anti-HA was added to the lysates at a concentration of 0.4 mg/ml. After incubation at 48C for 120 min, 25 ml of a 50% solution of protein ASepharose in lysis buer was added and the incubation was continued for another 60 min.
For detection of ubiquitinated cyclin D1, U2OS cells that had been co-transfected with pCDNA3-ubiquitin MYC and pCDNA3-cyclin D1 HA , were treated for 4 h prior to harvest with the peptide aldehyde leucinyl-leucinyl-norleucinyl (LLnL) diluted to 100 mM or with DMSO carrier alone.
In vitro ubiquitination assay
The in vitro ubiquitination assays were carried as described earlier (Germain et al., 2000) .
Pulse chase
Cells were washed twice in PBS and then incubated at 378C either for 30 min (cyclin D1) or 1 h (p27) in methionine and cysteine free medium. Cells were metabolically labelled at 378C for either 30 min (cyclin D1) or 4 h (p27) with 200 mCi / ml of Trans 35 S label (NEN life Sciences), washed twice in PBS and then chased in complete medium for the indicated times. Cyclin D1 and p27 protein was immunoprecipitated from 600 mg total protein at each time point, resolved by electrophoresis in 12% SDS-polyacrylamide gels and detected by autoradiography.
Immunohistochemical staining
Cells were plated in 6-well tissue culture plates containing a sterile coverslip at a density of 2.5610 5 cells per well. The following day, cells were transfected for 24 h. For staining the cells were ®xed in 4% paraformaldehyde-PBS for 15 min at RT, then permeabilised using PBS containing 0.1% Triton X-100/0.5% BSA for 5 min at RT. A blocking solution of 2% BSA/PBS was applied to the cells for 15 min at RT. Primary and secondary antibodies were prepared in 2% BSA/ PBS at a concentration of 1 : 100 and applied to cells for 1 h at RT. Following antibody incubations, cells were washed with 1 ml of 0.05% Triton X-100/PBS for 2 min, then rinsed in PBS. Coverslips were removed from wells and mounted on glass slides, in Citi¯uor AF1 (Alltech) mounting solution.
Subcellular fractionation
Cells were harvested using an hypotonic buer (10 mM Tris, pH 7.5, 10 mM NaCl, 3 mM MgCl 2 0.5% NP-40) and lysed using 25 strokes of a Dounce homogenizer. Nuclei were pelleted in a microfuge at 2000 g for 1 min and the supernatant retained as the cytosolic fraction. After three washes in hypotonic buer, the nuclei were lysed in NP-40 lysis buer with sonication. Both fractions were clari®ed at 13 000 g for 15 min.
GST binding assay
Ten ml of 35 S-labelled Skp2 or CTV-Skp2 was mixed with either 5 ml GST (1 mg/ml) or 5 ml GST-Skp1 (1 mg/ml) and 35 ml of 50% slurry of glutathione agarose beads. The volume was adjusted to 250 ml using Binding buer (25 mM HEPES pH 7.5, 12.5 mM MgCl 2 , 20% glycerol, 0.1% NP40, 150 mM KCl, 150 mg/ml BSA). Samples were incubated on a rotating wheel for 2 h at 48C. The beads were washed six times with 1 ml NETN buer (0.5% NP40, 20 mM Tris pH 8, 100 mM NaCl, 1 mM EDTA), resuspended in 40 ml 26SDS sample buer and run on a 12% SDS ± PAGE gel. Following migration the gel was ®xed in 20% methanol/10% acetic acid for 30 min, dried and exposed to Kodak XR ®lm overnight at 7708C.
